MRD May Predict Relapse in NSCLC

Abstract Circulating tumor DNA (ctDNA) may be a useful biomarker for minimal residual disease (MRD) in patients with early-stage non–small cell lung cancer—and MRD may be a good predictor of relapse. In the TRACERx study, a ctDNA assay confirmed MRD negativity in more than 99% of patients—and detected MRD in patients who relapsed before their disease was picked up by standard imaging.